Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Brinter develops 3D bioprinting technology for regenerative implants. The company serves the medical and biotech industries focused on human repair applications.
2 investors
Brooklyn Health builds objective, sensitive measurement tools for symptoms of neurological and neuropsychiatric disorders, aimed at reducing risk in CNS drug development. It serves the biotech and pharmaceutical sector with a team of clinicians, scientists, engineers, designers, and operators focused on the measurement problem in health.
2 investors
Unreal Milk produces lab-grown whole cow milk using cellular agriculture technology. The company targets consumers seeking sustainable dairy alternatives.
2 investors
BullFrog AI develops AI/ML software for drug discovery that harmonizes fragmented biomedical data and analyzes complex multimodal datasets to identify patient subgroups, drug targets, and biomarkers. It serves biopharma and life sciences teams working on clinical trials and translational research.
2 investors
Bullseye Biosciences uses in-cell directed evolution to discover functional therapeutic molecules against challenging intracellular targets such as protein–protein interactions and transcriptional regulation. Its platform selects molecules like macrocyclic and stapled peptides based on their biological effect inside living cells, with applications in oncology, immunology, and other serious diseases.
2 investors
Bunsen is a creative agency that helps science and deep technology companies develop strategic narratives and design to communicate their innovations to investors and the public. The firm combines scientific expertise, venture capital insight, and creative design to serve founders in biotech, life sciences, and frontier technology sectors.
2 investors
ByBug is a biotech startup that uses genetic engineering and black soldier fly (Hermetia illucens) biomanufacturing to produce oral biological feed additives that prevent diseases such as Caligus in salmon and White Spot Syndrome Virus in shrimp. Its functional additives are mixed into existing animal feed for aquaculture producers, with a stated focus on the Chilean salmon industry and the global shrimp market.
2 investors
CaaMTech is a pharmaceutical drug discovery company that engineers novel small-molecule psychedelic-inspired therapeutics for mental health treatment through structure-activity optimization and safety screening. The company conducts fundamental research on tryptamine compounds, develops intellectual property, and aims to support the psychedelics industry with scientific foundations and validated drug candidates.
2 investors
Caedo Oncology develops therapeutic antibodies for cancer treatment, leveraging deep immunology and antibody engineering expertise.
2 investors
Caffree develops a powdered enzymatic system for precision decaffeination that converts caffeine into theobromine, allowing coffee brands to control caffeine levels without changing flavor. It targets coffee brands, cold brew and RTD beverage manufacturers, and co-packers, integrating into existing production equipment.
2 investors
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases. Its drug candidates target conditions such as acute pancreatitis, acute kidney injury, and pulmonary arterial hypertension.
2 investors
CALCIVIS develops the CALCIVIS Imaging System, a chairside diagnostic device that provides real-time assessment of enamel demineralization and tooth decay activity to support preventive dentistry. The FDA-approved and UKCA-marked system is aimed at dental clinicians managing caries and erosion.
2 investors
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.
2 investors
Plant cell culture company producing cultivated cocoa and coffee without traditional crops.
2 investors
2 investors
2 investors
Calliditas is a biopharmaceutical company developing and commercializing treatments for renal and other conditions, including TARPEYO/Nefecon/Kinpeygo (budesonide) for primary IgA nephropathy and NOX inhibitor candidates such as setanaxib for fibrotic diseases and cancer. It works with commercial partners including Everest Medicines and STADA to bring its therapies to markets such as the US, UK, EU, and China.
2 investors
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease). The company is advancing the drug into global Phase 2 clinical development.
2 investors
Canaery develops a nose-computer interface that combines animal olfaction with neurotechnology and AI to detect substances and diagnose diseases. The technology enables working animals to identify contraband, pests, and health conditions for security, pest control, and medical screening applications.
2 investors
Canomiks is a life sciences company focused on developing treatments and research in diabetes, cardiovascular disease, and related areas, drawing on expertise in pharmacology, genomics, and bioinformatics.
2 investors
Canopy Biosciences (Bruker Spatial Biology) develops spatial biology instruments and assays for analyzing gene expression, RNA, and proteins in tissue samples. The company serves research institutions, academic medical centers, and clinical laboratories studying oncology, biomarker discovery, and disease mechanisms.
2 investors
Canurta Therapeutics develops multi-target botanical drugs using its AI-backed PolyKye platform to identify bioactive compounds and guide compound selection, disease targeting, and formulation. Its therapies target inflammation and neurological diseases, with a lead candidate (CNR-401) aimed at Amyotrophic Lateral Sclerosis (ALS).
2 investors
Capable is a vertically integrated, AI-enabled deeptech platform developing peptide and nucleotide therapeutics using automated polymer synthesis, drawing on rare human genetic variants. Its first programs focus on sleep, targeting rare sleep diseases such as narcolepsy and hypersomnia with therapeutics aimed at improving cognitive performance under sleep deprivation.
2 investors
Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
2 investors